Clinical Trial Update: A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke [Phase 2]

View source ↗

Summary

Phase 2 open-label trial evaluating etavopivat's effect on transcranial Doppler velocities in pediatric sickle cell patients at high risk for stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Etavopivat (Etavopivat)

Snippet

Sponsor: Forma Therapeutics, Inc. | Conditions: Sickle Cell Disease | Phase 2 | Status: RECRUITING